Liraglutide
LYDIA
Novo Nordisk · Phase 3 · Completed · Enrollment 90
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Liraglutide | n/r | n/r | n/r | n/r |
| Sitagliptin | n/r | n/r | n/r | n/r |
Not shown
- Liraglutide: endpoint not reported
- Sitagliptin: endpoint not reported